Market Overview - The animal health sector increased by 1.34% on September 1, with Jinhe Biology leading the gains [1] - The Shanghai Composite Index closed at 3875.53, up 0.46%, while the Shenzhen Component Index closed at 12828.95, up 1.05% [1] Stock Performance - Jinhe Biology (002688) closed at 7.53, up 6.06% with a trading volume of 875,700 shares and a turnover of 651 million yuan [1] - Other notable performers included *ST Lvkang (002868) with a 5.02% increase, and Shunlian Biology (688098) with a 1.78% increase [1] - The overall trading data for the animal health sector is summarized in the provided table [1] Capital Flow - The animal health sector saw a net inflow of 26.58 million yuan from institutional investors, while retail investors experienced a net outflow of 7.06 million yuan [2] - The detailed capital flow for individual stocks indicates varying levels of institutional and retail participation [3] Individual Stock Analysis - Jinhe Biology had a net inflow of 88.59 million yuan from institutional investors, while retail investors showed a net outflow of 37.91 million yuan [3] - Other stocks like Kexin Biology (688526) and *ST Lvkang (002868) also experienced mixed capital flows, with significant retail outflows [3]

Market Overview - The animal health sector experienced a decline of 1.01% on August 28, with *ST Lvkang leading the drop [1] - The Shanghai Composite Index closed at 3843.6, up 1.14%, while the Shenzhen Component Index closed at 12571.37, up 2.25% [1] Stock Performance - Notable gainers included: - Qudongli (838275) with a closing price of 11.07, up 5.23% [1] - Xianfeng Holdings (002141) at 4.19, up 1.21% [1] - Zhongmu Co. (600195) at 7.63, up 0.66% [1] - Major decliners included: - *ST Lvkang (002868) at 27.20, down 3.51% [2] - Shenyuan Bio (688098) at 12.59, down 2.70% [2] - KQ Bio (688526) at 18.40, down 1.55% [2] Capital Flow - The animal health sector saw a net outflow of 136 million yuan from institutional investors, while retail investors contributed a net inflow of 101 million yuan [2] - The detailed capital flow for key stocks showed: - Zhongmu Co. had a net outflow of 18.59 million yuan from institutional investors [3] - *ST Lvkang experienced a significant net outflow of 7.31 million yuan from institutional investors [3] - Retail investors showed a net inflow of 5.64 million yuan into *ST Lvkang [3]

Core Insights - Yongshun Biological (stock code: 839729) reported a revenue of 122 million yuan for the first half of 2025, representing a year-on-year increase of 2.14% [1] - The net profit attributable to shareholders reached 19.72 million yuan, up 26.95% year-on-year, with a 50.72% increase when excluding the impact of share-based payments, indicating strong growth momentum [1] Business Performance - The core business of pig vaccines showed a significant recovery, with sales of live pig vaccines increasing by 13.95% year-on-year, driven by rising pig prices and increased enthusiasm among small and medium-sized farmers [1] - The revenue from the pig circovirus vaccine increased by 2.84 million yuan, becoming a new growth point for performance [1] Research and Development - The company increased its R&D investment to 10.25 million yuan, accounting for 8.42% of revenue, and successfully obtained new veterinary drug certificates and production licenses for several projects [1] - The company received clinical approval and invention patent authorization for multiple projects, laying a solid foundation for future development [1] Cost Management - Through continuous optimization of production processes, the unit costs of the main products, including the pig pseudorabies and avian influenza vaccines, decreased by approximately 11% and 9% respectively, significantly enhancing product competitiveness [1] - The company improved operational efficiency through supply chain optimization and refined management [1] Marketing Strategy - The company adheres to a "channel sinking, marketing terminal" strategy, resulting in a 22.60% year-on-year increase in domestic distributor revenue [2] - Significant success in overseas market expansion, particularly in Vietnam and Egypt, where revenue reached 13.03 million yuan, a substantial year-on-year growth of 88.61% [2] Future Outlook - Yongshun Biological will continue to pursue an innovation-driven development strategy, focusing on market demand, optimizing product structure, and enhancing product quality and service levels to consolidate and expand market advantages [2]

Core Insights - Yongshun Biological (839729.BJ) reported strong revenue and net profit growth in the first half of 2025, driven by a recovery in the pig farming industry and increased competition [1][2] - The company achieved a revenue of 122 million yuan, a year-on-year increase of 2.14%, and a net profit of 19.72 million yuan, up 26.95% [2] - The gross profit margin improved by 1.85 percentage points, supported by a higher proportion of high-margin pig vaccines and a decrease in raw material costs [4] Revenue Growth - The growth in revenue was primarily attributed to the recovery of the pig vaccine market, with sales volume of live pig vaccines increasing by 13.95% [2] - Other vaccine revenues saw a significant increase of 63.86%, with the income from pig circovirus vaccines rising by 2.84 million yuan [2][4] - Domestic dealer revenue grew by 22.60% to 47.04 million yuan, while overseas revenue reached 13.03 million yuan, an increase of 88.61% [4] Profitability Enhancement - The company’s net profit attributable to shareholders, excluding share-based payment effects, surged by 50.72% to 23.41 million yuan [2] - Cost control measures and operational efficiency improvements contributed to the rapid growth in net profit [4][12] R&D and Innovation - Yongshun Biological invested 10.25 million yuan in R&D, accounting for 8.42% of its revenue, highlighting its commitment to technological innovation [9] - The company received several important certifications and patents, enhancing its product line and future growth potential [9] - Production cost reductions were achieved through process innovations, with costs for certain products decreasing by approximately 11% and 9% [12] Future Outlook - The company aims to maintain its competitive edge in the veterinary biological products industry by focusing on quality and innovation [12] - Plans include increasing R&D investments and optimizing product offerings to capitalize on market demand [12]

证券代码：839729 证券简称：永顺生物 公告编号：2025-081 广东永顺生物制药股份有限公司 独立董事候选人声明与承诺（亓文宝） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 本人亓文宝，已充分了解并同意由提名人广东永顺生物制药股份有限公司提 名为广东永顺生物制药股份有限公司第五届董事会独立董事候选人。本人公开声 明，本人具备独立董事任职资格，保证不存在任何影响本人担任广东永顺生物制 药股份有限公司独立董事独立性的关系，具体声明并承诺如下： 一、本人已同时符合以下条件： （一）具备上市公司运作的基本知识，熟悉相关法律法规、部门规章、规范 性文件及北交所业务规则； （二）具有五年以上履行独立董事职责所必需的法律、会计或者经济等工作 经验； （三）具有良好的个人品德，不存在重大失信等不良记录； （四）北交所规定的其他条件。 二、本人任职资格符合下列法律法规、部门规章和规范性文件及北交所业 务规则的要求： （一）《公司法》关于董事任职资格的规定； （二）《中华人民共和国公务员法》的相关规定； （三） ...

证券代码：839729 证券简称：永顺生物 公告编号：2025-079 广东永顺生物制药股份有限公司 拟续聘 2025 年度会计师事务所公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 涉及会计师事务所提供的资料、信息，会计师事务所保证其提供、报送或披 露的资料、信息真实、准确、完整，不得有虚假记载、误导性陈述或者重大遗漏。 一、拟续聘会计师事务所的基本情况 （一）机构信息 公司拟聘任天健会计师事务所（特殊普通合伙）为 2025 年年度的审计机构。 1.基本信息 2024 年上市公司审计客户家数：756 家 2024 年上市公司审计客户前五大主要行业： 会计师事务所名称：天健会计师事务所（特殊普通合伙） 成立日期：2011 年 7 月 18 日 组织形式：特殊普通合伙 注册地址：浙江省杭州市西湖区灵隐街道西溪路 128 号 首席合伙人：钟建国 2024 年度末签署过证券服务业务审计报告的注册会计师人数：904 人 2024 年收入总额（经审计）：29.69 亿元 2024 年审计业务收入（经审计）： ...

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 证券代码：839729 证券简称：永顺生物 公告编号：2025-080 广东永顺生物制药股份有限公司董事任命公告 提名亓文宝先生为公司独立董事，任职期限至第五届董事会届满之日止，本次选举 尚需提交股东会审议，自股东会决议通过之日起生效。该人员持有公司股份 0 股，占公 司股本的 0%，不是失信联合惩戒对象。 一、董事任命的基本情况 广东永顺生物制药股份有限公司（以下简称"公司"）于 2025 年 8 月 25 日召开第 五届董事会第十一次会议，审议通过了《关于选举公司第五届董事会非独立董事的议案》 《关于选举公司第五届董事会独立董事的议案》。 提名吴锋先生为公司董事，任职期限至第五届董事会届满之日止，本次选举尚需提 交股东会审议，自股东会决议通过之日起生效。该人员持有公司股份 480,000 股，占公 司股本的 0.1756%，不是失信联合惩戒对象。 公司董事候选人的任职资格符合法律法规、部门规章、业务规则和公司章程等规定。 本次任命未导致董事会中兼任高级管 ...

证券代码：839729 证券简称：永顺生物 公告编号：2025-043 广东永顺生物制药股份有限公司 关于取消监事会并拟修订《公司章程》公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、修订内容 根据《公司法》及《上市公司章程指引》以及《关于新<公司法>配套制度规 则实施相关过渡期安排》等相关规定，公司拟修订《公司章程》的部分条款，修 订对照如下： | 原规定 | 修订后 | | --- | --- | | 第一条 为维护广东永顺生物制药股份 | 第一条 为维护广东永顺生物制药股份 | | 有限公司（以下简称"公司"）、股东和 | 有限公司（以下简称"公司"）、股东、 | | 债权人的合法权益，规范公司的组织和 | 职工和债权人的合法权益，规范公司的 | | 行为，根据《中华人民共和国公司法》 | 组织和行为，根据《中华人民共和国公 | | （以下简称"《公司法》"）、《中华人民 | 司法》（以下简称"《公司法》"）、《中华 | | 共和国证券法》（以下简称"《证券 | 人民共和国证券法》（以下 ...

广东永顺生物制药股份有限公司 独立董事提名人声明与承诺 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 证券代码：839729 证券简称：永顺生物 公告编号：2025-082 （二）具有五年以上履行独立董事职责所必需的法律、会计或者经济等工作 经验； （三）具有良好的个人品德，不存在重大失信等不良记录； （四）北交所规定的其他条件。 二、被提名人任职资格符合下列法律法规、部门规章、规范性文件及北交所 业务规则的要求： （一）《公司法》关于董事任职资格的规定； （二）《中华人民共和国公务员法》的相关规定； （三）中国证监会《上市公司独立董事管理办法》的相关规定； （四）中共中央纪委、中共中央组织部《关于规范中管干部辞去公职或者退 （离）休后担任上市公司、基金管理公司独立董事、独立监事的通知》的相关规 定； 提名人广东永顺生物制药股份有限公司董事会，现提名亓文宝先生为广东永 顺生物制药股份有限公司第五届董事会独立董事候选人，并已充分了解被提名人 职业、学历、职称、详细的工作经历、全部兼职、有无重大失信等不良 ...

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 广东永顺生物制药股份有限公司（以下简称"公司"）根据《公司章程》《公 司董事、高级管理人员薪酬管理制度》等相关制度，结合公司经营发展实际情况 并参考行业、地区薪酬水平，制定了公司董事、高级管理人员薪酬方案。现将方 案具体内容公告如下： 一、基本情况 （一）适用对象：公司董事、高级管理人员 证券代码：839729 证券简称：永顺生物 公告编号：2025-083 广东永顺生物制药股份有限公司 关于董事、高级管理人员薪酬方案的公告 （一）2025 年 8 月 21 日，公司召开第五届董事会薪酬与考核委员会第五次 会议，审议通过了《关于制定公司高级管理人员薪酬方案的议案》；审议了《关 于制定公司董事薪酬方案的议案》，鉴于本议案所有委员均为关联董事，全部回 避表决，会议同意将该议案提交董事会审议。 （二）2025 年 8 月 25 日，公司召开第五届董事会第十一次会议，审议通过 了《关于制定公司高级管理人员薪酬方案的议案》，该议案无需提交股东会审议； 审议了《关于制 ...